Hsiao Y C, Lin Y Z, Chen W, Wu K W
Department of Pediatrics, Taipei Municipal Chung-Hsiao Hospital, Republic of China.
Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1994 May-Jun;35(3):244-9.
Subjective clinical observations have suggested that nebulized bronchodilators are helpful in the treatment of some wheezy infants. Although the role of beta 2-agonists in the management of acute asthma in infants and very young children remains controversial, the use of beta 2-adrenergic agents in this age group has been widespread. beta 2-agonists nebulization continues to be the first-line treatment for acute attack of asthma, irrespective of age, in some institutes, but their uses are not without side effect especially in young wheezy infants. We report three cases of respiratory failure occurred after treatment with nebulized beta 2 bronchodilator in infants with chronic lung disease and acute wheezing. All the 3 cases were victims of prematurity. Case 1 was a case of Wilson-Mikity syndrome; case 2 was a case of bronchopulmonary dysplasia; and case 3 was a case of repeatedly wheezing infant. All 3 cases had severely wheezy dyspnea with retraction before nebulized beta 2 bronchodilator treatment. Respiratory failure was found 5 to 10 minutes after the treatment. We suggest that it must be very careful in the treatment of severely wheezy infants with beta 2-agonist nebulization, especially in cases with histories of prematurity and chronic lung disease. It is necessary to carefully monitor the vital signs of the infants during beta 2 agonist nebulization.
主观临床观察表明,雾化支气管扩张剂有助于治疗一些喘息性婴儿。尽管β2受体激动剂在婴幼儿急性哮喘治疗中的作用仍存在争议,但该年龄组中β2肾上腺素能药物的使用已很普遍。在一些机构中,无论年龄大小,β2受体激动剂雾化仍然是哮喘急性发作的一线治疗方法,但其使用并非没有副作用,尤其是在喘息性婴儿中。我们报告了3例慢性肺病合并急性喘息的婴儿在接受雾化β2支气管扩张剂治疗后发生呼吸衰竭的病例。这3例均为早产儿。病例1为威尔逊-米基蒂综合征;病例2为支气管肺发育不良;病例3为反复喘息婴儿。在雾化β2支气管扩张剂治疗前,所有3例均有严重的喘息性呼吸困难伴三凹征。治疗后5至10分钟发现呼吸衰竭。我们建议,在使用β2受体激动剂雾化治疗严重喘息婴儿时必须非常谨慎,尤其是对于有早产和慢性肺病病史的病例。在β2受体激动剂雾化治疗期间,有必要仔细监测婴儿的生命体征。